Windtree Therapeutics, Inc. (NasdaqCM: WINT) showcased encouraging results from the Phase 2b SEISMiC study of istaroxime, its novel investigational therapy for early cardiogenic shock, at the ...
WARRINGTON, Pa. - Windtree Therapeutics, Inc. (NASDAQ:WINT), a biotechnology firm specializing in the development of therapies for critical diseases and currently valued at $1.44 million market ...
The following is a summary of “Corticosteroids in Cardiogenic Shock: A Retrospective Analysis of the Medical Information Mart ...
Photo Credit: The Hildner Family. The Society for Cardiovascular Angiography and Interventions (SCAI) today announced that one of its founding members, Frank J. Hildner, MD, for whom the annual ...
Advances in critical care therapies for patients with cardiogenic shock (CS), including temporary mechanical circulatory support and multidisciplinary shock teams, have led to improved survival to ...
Welcome to Washington’s new normal. President Trump promised shock and awe when he was elected, and his Inauguration Day at times felt like an effort to overwhelm his critics, his opponents and ...
Background Cardiogenic shock (CS) induced by severe aortic stenosis (AS ... characterised by relevant heterogeneity and did not report outcomes according to the SCAI classification. A further relevant ...
THE MEMO HAS CLEARLY GONE OUT: The phrase the incoming Trump administration is using to describe its opening days is “shock and awe.” Tom Homan, the incoming designated border czar, when asked during ...
Acute myocardial infarction-related cardiogenic shock (AMI-CS) is a severe, life-threatening condition characterised by inadequate tissue perfusion due to the heart’s inability to pump blood ...
Although mortality risk prediction in cardiogenic shock (CS) is possible, assessing the impact of the multitude of therapeutic efforts on outcomes is not straightforward. We assessed whether a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results